Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson’s Disease
Open Access
- 18 November 2015
- journal article
- research article
- Published by Wiley in Parkinson's Disease
- Vol. 2015, 1-11
Abstract
Aim. In this study we examined the influence of tetrandrine (Tet) on the neuroprotective effects of glutathione (GSH) in the 6-hydroxydopamine- (6-OHDA-) lesioned rat model of Parkinson’s disease (PD).Methods. Levels in the redox system, dopamine (DA) metabolism, dopaminergic neuronal survival, and apoptosis of the substantia nigra (SN) and striatum, as well as the rotational behavior of animals were examined after a 50-day administration of GSH + Tet (or GSH) and/or L-3,4-dihydroxyphenylalanine (L-dopa) to PD rats. Ethics Committee of Huashan Hospital, Fudan University approved the protocol (number SYXK2009-0082).Results. Administration of GSH or Tet alone did not show any significant effects on the factors evaluated in the PD rats. However, in the GSH + Tet group, we observed markedly decreased oxidative damage, inhibition of DA metabolism and enhanced DA synthesis, increased tyrosine hydroxylase- (TH-) immunopositive neuronal survival, and delayed apoptosis of dopaminergic neurons in the SN. Animal rotational behavior was improved in the GSH + Tet group. Additionally, coadministration of GSH + Tet appeared to offset the possible oxidative neurotoxicity induced by L-dopa.Conclusion. In this study, we demonstrated that tetrandrine allowed occurrence of the neuroprotective effect of glutathione probably due to inhibition of P-glycoprotein on 6-hydroxydopamine-lesioned rat models of Parkinson’s disease, including rats undergoing long-term L-dopa treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81170322, 11ZR1405300, 2012052)
- Shanghai Natural Science Foundation of China (81170322, 11ZR1405300, 2012052)
- Shanghai Municipal Outstanding Talent Development Foundation (81170322, 11ZR1405300, 2012052)
This publication has 34 references indexed in Scilit:
- How to treat Parkinson’s disease in 2013Clinical Medicine, 2013
- Recent Advances in the Treatment of Neurodegenerative Diseases Based on GSH Delivery SystemsOxidative Medicine and Cellular Longevity, 2012
- A novel neuroprotective therapy for Parkinson’s disease using a viral noncoding RNA that protects mitochondrial Complex I activityJournal of Experimental Medicine, 2011
- Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrierTrends in Pharmacological Sciences, 2010
- A Disruption in Iron-Sulfur Center Biogenesis via Inhibition of Mitochondrial Dithiol Glutaredoxin 2 May Contribute to Mitochondrial and Cellular Iron Dysregulation in Mammalian Glutathione-Depleted Dopaminergic Cells: Implications for Parkinson's DiseaseAntioxidants & Redox Signaling, 2009
- Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System PharmacotherapyPharmacological Reviews, 2008
- Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson’s disease: A dynamic modelNeuroscience, 2007
- Pharmacological actions of tetrandrine in inflammatory pulmonary diseases.2002
- Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neuronesNeuroReport, 1996
- Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.1993